Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Lenalidomide. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN known ✓ | Q96SW2 | 13/20 | 1.00 |
| ▸ | DDB1 known ✓ | Q16531 | 3/20 | 1.00 |
| ▸ | IKZF3 | Q9UKT9 | 4/20 | 1.00 |
| ▸ | IKZF1 | Q13422 | 3/20 | 1.00 |
| ▸ | TNF | P01375 | 3/20 | 1.00 |
| ▸ | IL1B | P01584 | 3/20 | 1.00 |
| ▸ | BRD4 | O60885 | 1/20 | 1.00 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.62 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.55 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.55 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.55 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.55 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.55 |
| ▸ | TSHR | P16473 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | MAP1LC3B | Q9GZQ8 | 2/20 | 0.53 |
| ▸ | IKZF2 | Q9UKS7 | 2/20 | 0.52 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Lenalidomide SCHEMBL32978 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL30876939 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL17999103 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18825 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192655 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL868339 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL29377496 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192663 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL10192650 | 1.00 | CRBN (1.00) | CRBNIKZF3IKZF1DDB1TNF | |
| Lenalidomide SCHEMBL18917500 | 0.99 | CRBN (0.97) | CRBNIKZF3IKZF1DDB1TNF |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 175 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118878511-A | Adamantane derivative, PROTAC degradation agent targeting ER, preparation method and application thereof | 晨伫(杭州)生物科技有限责任公司 | 2024-11-01 | — | — | CN | claimed |
| US-20240327374-A1 | LENALIDOMIDE PROCESS | CHATURVEDI AKSHAY KANT (IN) | 2024-10-03 | — | — | US | claimed |
| US-20240293312-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(4-AMINO-1-OXO-1, 3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2, 6-DIONE | RISHABH SHAH (IN) | 2024-09-05 | — | — | US | claimed |
| CN-116354927-A | HDAC degradation agent using alkane or fatty acid as connecting chain, preparation method and application thereof | 杭州医学院 | 2023-06-30 | — | — | CN | claimed |
| EP-4171550-A1 | METHODS FOR TREATING CANCER WITH COMBINATION THERAPIES | Celgene Corporation (US) | 2023-05-03 | — | — | EP | claimed |
| WO-2023016075-A1 | DIHYDRO-2H-ISOINDOLE ESTER COMPOUND | 上海贵之言医药科技有限公司 | 2023-02-16 | — | — | WO | claimed |
| CN-114933584-B | dihydro-2H-isoindole ester compound | 上海贵之言医药科技有限公司 | 2022-12-27 | — | — | CN | claimed |
| CN-115298223-A | Glypican-2 binding moiety, chimeric antigen receptor and use thereof | 南京传奇生物科技有限公司 | 2022-11-04 | — | — | CN | claimed |
| CN-114933584-A | dihydro-2H-isoindole ester compound | 上海贵之言医药科技有限公司 | 2022-08-23 | — | — | CN | claimed |
| CN-117654577-B | Heterogeneous nano heterojunction photocatalyst and preparation method and application thereof | Quzhou College of Technology (CN) | 2026-05-26 | — | — | CN | disclosed |
| US-20250388691-A1 | METHODS FOR TREATING LYMPHOMA | XENCOR INC (US) | 2025-12-25 | — | — | US | disclosed |
| WO-2025235363-A1 | CYCLIN-DEPENDENT KINASE 4 DEGRADERS | BLUEPRINT MEDICINES CORPORATION (US) | 2025-11-13 | — | — | WO | disclosed |
| EP-4611798-A1 | METHODS OF TREATMENT WITH T CELL THERAPY AND IMMUNOMODULATORY AGENT MAINTENANCE THERAPY | CELGENE CORPORATION (US) | 2025-09-10 | — | — | EP | disclosed |
| EP-4611750-A1 | COMBINATION THERAPIES COMPRISING A CDK9 INHIBITOR FOR CANCER | Vincerx Pharma, Inc. (US) | 2025-09-10 | — | — | EP | disclosed |
| CN-114206340-A | Methods of treating follicular lymphoma using anti-CD 79B immunoconjugates | 豪夫迈·罗氏有限公司 | 2022-03-18 | — | — | CN | disclosed |
| WO-2022053652-A1 | COMBINATION THERAPY FOR CANCER | ENGMAB SÀRL (CH) | 2022-03-17 | — | — | WO | disclosed |
| CN-110357889-B | Protein degradation targeting compound, anti-tumor application thereof, intermediate thereof and application of intermediate | 上海科技大学 | 2022-03-15 | — | — | CN | disclosed |
| CN-114173810-A | Trispecific binding molecules directed against BCMA and uses thereof | 诺华股份有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114174299-A | Degradation of Bruton's Tyrosine Kinase (BTK) by conjugation of BTK inhibitors to E3 ligase ligands and methods of use | 百济神州有限公司 | 2022-03-11 | — | — | CN | disclosed |
| CN-114134113-A | Natural killer cell and use thereof | 人类起源公司 | 2022-03-04 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240293312-A1 | PHARMACEUTICAL COMPOSITIONS OF 3-(4-AMINO-1-OXO-1, 3 DIHYDRO-ISOINDOL-2-YL)-PIPERIDINE-2, 6-DIONE | MCL1, MALT1, BCL9 | CRBN 834/4885DDB1 1467/4885IKZF3 329/4885 |
| US-20250388691-A1 | METHODS FOR TREATING LYMPHOMA | IGLV6-57, BCL6, MALT1 | CRBN 336/4885DDB1 92/4885IKZF3 41/4885 |
| US-20240327374-A1 | LENALIDOMIDE PROCESS | IL1R1, MALT1, RAP2C | CRBN 141/4885DDB1 1718/4885IKZF3 518/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.